Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. has filed a prospectus for the resale by selling shareholders of up to 7,256,474 ordinary shares. The shares consist of issued shares and shares issuable upon exercise or conversion of a pre-funded warrant, transaction warrant, initial warrants and convertible notes issued in connection with the Strategic Acquisition.
The company is not selling shares here and will receive no proceeds from resales; selling shareholders will pay resale commissions. The prospectus cites a last reported sale price of $7.38 per share on April 24, 2026 and discloses certain shareholder ownership limits and plan‑of‑distribution methods.
Lifeward Ltd. has given notice that the employment of Jeannine Lynch, its Vice President of Strategy and Market Access, will be terminated effective May 3, 2026. The departure is being treated as a termination without cause under her Employment Agreement dated July 9, 2021.
Ms. Lynch will receive severance and other benefits in line with that Employment Agreement. The company previously described the terms of this agreement in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 18, 2026.
Lifeward Ltd. director Sigsbee William Mark reported an equity compensation grant. He received 11,485 ordinary shares in the form of restricted stock units at a price of $0.00 per share, bringing his direct holdings reported in this filing to 11,485 shares.
The 11,485 RSUs were granted on March 25, 2026 under Lifeward’s 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments, starting three months after the grant date, meaning the award converts into shares gradually over a one‑year period if service conditions are met.
Lifeward Ltd. director Sigsbee William Mark filed an initial insider ownership report on Form 3. This filing establishes his status as a reporting person for the company but shows no insider stock purchases, sales, exercises, gifts, or other transactions at this time.
Rozenbaum Moshe H reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Moshe H Rozenbaum reported an equity compensation grant of 11,485 ordinary shares in the form of restricted stock units (RSUs). The award was granted on March 25, 2026 under the company’s 2025 Incentive Compensation Plan at a grant price of $0.0000 per share.
The 11,485 RSUs vest ratably in four equal quarterly installments starting three months from the grant date, meaning the director earns the shares over time rather than all at once. After this grant, Rozenbaum’s reported direct holdings total 11,485 ordinary shares.
Lifeward Ltd. director Moshe H Rozenbaum filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The structured data shows no reported transactions or derivative positions at this time.
Lifeward Ltd. reported that it has restored compliance with a key Nasdaq corporate governance rule. The company previously fell out of compliance with Nasdaq Listing Rule 5605(c)(2)(A) after director Hadar Levy resigned from the Board and its Audit Committee, leaving the committee below the required three members.
Nasdaq staff sent written notice on March 30, 2026, acknowledging the appointments of Moshe Rozenbaum, William Mark Sigsbee and Yehuda Reznick to the Audit Committee and confirming that Lifeward now meets the three-member requirement. Nasdaq stated the company is again in compliance with the rule and that the matter is closed.
Lifeward Ltd. reported that Chief Financial Officer Adar Almog received a grant of stock options on 39,934 ordinary shares of the company. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The grant vests over four years, with 25% of the underlying shares vesting on March 25, 2027, and the remaining shares vesting in equal monthly installments over the following 36 months, contingent on continued service. Following this grant, Almog holds options to acquire 39,934 shares, reflecting routine, compensation-related equity rather than an open-market share purchase.
Lifeward Ltd. President and CEO Grant William Mark received a grant of stock options covering 172,698 ordinary shares. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The award vests over four years, with 25% of the underlying shares vesting on March 25, 2027. The remaining 75% vests in equal monthly installments over the following 36 months, contingent on his continued service, with potential acceleration under the applicable plan and grant terms.